Curetis Publishes Full-Year 2017 Financial Results and Updated Guidance For 2018
in portfolio news
- Received U.S. FDA clearance for Unyvero System and Unyvero LRT Cartridge; commercial U.S. roll-out initiated
- Launched two novel CE-IVD marked Unyvero Applications
- Strengthened global commercial footprint; expanded installed base
Curetis N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced financial results for the twelve months ended December 31, 2017 and provided an updated guidance for 2018.